Salud financiera de hoja de balance de Eagle Pharmaceuticals
Salud financiera controles de criterios 4/6
Eagle Pharmaceuticals tiene un patrimonio de accionistas total de $252.0M y una deuda total de $70.2M, lo que sitúa su ratio deuda-patrimonio en 27.8%. Sus activos y pasivos totales son $404.8M y $152.8M respectivamente. El BAIT de Eagle Pharmaceuticals es de $41.7M, por lo que su ratio de cobertura de intereses es de 7.2. Tiene efectivo e inversiones a corto plazo que ascienden a $15.4M.
Información clave
27.8%
Ratio deuda-patrimonio
US$70.19m
Deuda
| Ratio de cobertura de intereses | 7.2x |
| Efectivo | US$15.35m |
| Patrimonio | US$252.04m |
| Total pasivo | US$152.78m |
| Activos totales | US$404.82m |
Actualizaciones recientes sobre salud financiera
Is Eagle Pharmaceuticals (NASDAQ:EGRX) A Risky Investment?
Sep 21
Eagle Pharmaceuticals (NASDAQ:EGRX) Seems To Use Debt Quite Sensibly
Jun 21These 4 Measures Indicate That Eagle Pharmaceuticals (NASDAQ:EGRX) Is Using Debt Safely
Oct 27Recent updates
Is Eagle Pharmaceuticals (NASDAQ:EGRX) A Risky Investment?
Sep 21Calculating The Fair Value Of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX)
Jul 13Eagle Pharmaceuticals (NASDAQ:EGRX) Seems To Use Debt Quite Sensibly
Jun 21These 4 Measures Indicate That Eagle Pharmaceuticals (NASDAQ:EGRX) Is Using Debt Safely
Oct 27Eagle files for FDA nod to start trial of CAL02 for bacterial pneumonia
Oct 12Eagle, Enalare get up to $50.3M US contract to develop ENA-001 for community drug overdose
Sep 27Eagle Pharma did not infringe on Endo’s vasopressin patents – appeals court
Aug 18Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Analysts Are More Bearish Than They Used To Be
Aug 15Eagle Pharmaceuticals Non-GAAP EPS of $1.56 misses by $1.80, revenue of $74.1M misses by $42.79M
Aug 09These 4 Measures Indicate That Eagle Pharmaceuticals (NASDAQ:EGRX) Is Using Debt Safely
Jul 06Eagle Pharmaceuticals, Inc.'s (NASDAQ:EGRX) Intrinsic Value Is Potentially 42% Above Its Share Price
Apr 29Is Eagle Pharmaceuticals (NASDAQ:EGRX) Using Too Much Debt?
Dec 16Shareholders May Be Wary Of Increasing Eagle Pharmaceuticals, Inc.'s (NASDAQ:EGRX) CEO Compensation Package
Jul 06Eagle Pharmaceuticals: A Potential Reopening Play
Jun 16Eagle Pharmaceuticals EPS misses by $0.49, misses on revenue
May 10Eagle Pharma's Treakisym RTD + rituximab OK'd in Japan for large b-cell lymphoma
Apr 30Eagle Pharmaceuticals (NASDAQ:EGRX) Could Easily Take On More Debt
Apr 15Eagle Pharmaceuticals, Inc.'s (NASDAQ:EGRX) Intrinsic Value Is Potentially 55% Above Its Share Price
Mar 25Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo ($187.3M) de EGRX superan a sus pasivos a corto plazo ($86.6M).
Pasivo a largo plazo: Los activos a corto plazo de EGRX ($187.3M) superan a sus pasivos a largo plazo ($66.2M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: El ratio deuda neta-patrimonio (21.8%) de EGRX se considera satisfactorio.
Reducción de la deuda: El ratio deuda-patrimonio de EGRX ha crecido de 25.2% a 27.8% en los últimos 5 años.
Cobertura de la deuda: El flujo de caja operativo de EGRX es negativo, por lo que la deuda no está bien cubierta.
Cobertura de intereses: Los pagos de intereses de la deuda de EGRX están bien cubiertos por el BAIT (7.2x cobertura).